Proton therapy developer Ion Beam Applications (IBA) has sold its RadioMed unit to IZI Medical Products for an estimated price of $14 million to $16 million.
RadioMed, which IBA acquired in 2003, makes Visicoil, an implantable fiducial marker for soft-tissue tumor localization designed to enhance the accuracy of radiation therapy planning and delivery. IZI develops, manufactures, and provides medical consumable devices for interventional radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery procedures.
IBA will retain ownership of the rest of its dosimetry products and business.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
